TYME -35% on phase-2/3 failure in pancreatic cancer: https://finance.yahoo.com/news/tyme-technologies-inc-provides-precision-115000819.html I’ve been a longstanding skeptic of TYME—e.g.: https://investorshub.advfn.com/boards/read_msg.aspx?message_id=137821688 https://investorshub.advfn.com/boards/read_msg.aspx?message_id=135684795